Showing results (511-520 of 542) with videos related to
Sort By:
Pageof 55
Gut|November 17, 2020
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersElizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.Blood|July 15, 2022
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphomaMahmoud Elsawy, Julio C Chavez, Irit Avivi, et al.JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.Cancer Discovery|September 1, 2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical TrialKhurum H Khan, David Cunningham, Benjamin Werner, et al.Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.Hepatology (Baltimore, Md.)|December 28, 2019
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ CellsPietro Carotenuto, Somaieh Hedayat, Matteo Fassan, et al.The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.Cancer Cell|July 10, 2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerAndrew Woolston, Khurum Khan, Georgia Spain, et al.Pageof 55